A narrative review of anti-obesity medications for obese patients with osteoarthritis

References

• Cui A, Li H, Wang D, et al. Global, regional prevalence, incidence and risk factors of knee osteoarthritis in population-based studies. EClinicalMedicine. 2020;29-30:100587.
   PubMedGoogle Scholar
• Safiri S, Kolahi AA, Smith E, et al. Global, regional and national burden of osteoarthritis 1990-2017: a systematic analysis of the Global Burden of Disease Study 2017. Ann Rheum Dis. 2020;79:819–828.
   PubMed Web of Science ®Google Scholar
• Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1204–1222.
   PubMed Web of Science ®Google Scholar
• The unrecognised burden of osteoarthritis: unmet needs in Europe. In The Economist. Edited by: The Economist Newspaper Limited 2022.
   Google Scholar
• Leifer VP, Katz JN, Losina E. The burden of OA-health services and economics. Osteoarthritis Cartilage. 2022;30(1):10–16.
   PubMed Web of Science ®Google Scholar
• Murphy L, Schwartz TA, Helmick CG, et al. Lifetime risk of symptomatic knee osteoarthritis. Arthritis Rheum. 2008;59(9):1207–1213.
   PubMed Web of Science ®Google Scholar
• Murphy LB, Helmick CG, Schwartz TA, et al. One in four people may develop symptomatic Hip osteoarthritis in his or her lifetime. Osteoarthritis Cartilage. 2010;18(11):1372–1379.
   PubMed Web of Science ®Google Scholar
• Qin J, Barbour KE, Murphy LB, et al. Lifetime risk of symptomatic hand osteoarthritis: the Johnston county osteoarthritis project. Arthritis Rheumatol. 2017;69(6):1204–1212.
   PubMed Web of Science ®Google Scholar
• Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. Lancet. 2019;393:1745–1759.
   PubMed Web of Science ®Google Scholar
• International ORS. OARSI white paper- OA as a serious disease. Edited by; 2016.
   Google Scholar
• Oo WM, Hunter DJ. Repurposed and investigational disease-modifying drugs in osteoarthritis (DMOADs). Ther Adv Musculoskelet Dis. 2022;14:1759720X221090297.
   PubMed Web of Science ®Google Scholar
• Waxman A. WHO global strategy on diet, physical activity and health. Food Nutr Bull. 2004;25(3):292–302.
   PubMedGoogle Scholar
• Kyle TK, Dhurandhar EJ, Allison DB. Regarding obesity as a disease: evolving policies and their implications. Endocrinol Metab Clin North Am. 2016;45(3):511–520.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Obesity and overweight (Geneva, Switzerland). Edited by 2021.
   Google Scholar
• Consultation WE. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363:157–163.
   PubMed Web of Science ®Google Scholar
• Jayawardana R, Ranasinghe P, Sheriff MH, et al. Waist to height ratio: a better anthropometric marker of diabetes and cardio-metabolic risks in South Asian adults. Diabetes Res Clin Pract. 2013;99(3):292–299.
   PubMed Web of Science ®Google Scholar
• CDC. Adult obesity facts. Edited by; 2021.
   Google Scholar
• Ward ZJ, Bleich SN, Cradock AL, et al. Projected U.S. state-level prevalence of adult obesity and severe obesity. N Engl J Med. 2019;381(25):2440–2450.
   PubMed Web of Science ®Google Scholar
• Evaluation IfHMa. High body-mass index — level 2 risk. Edited by; 2019.
   Google Scholar
• Hall KD, Kahan S. Maintenance of lost weight and long-term management of obesity. Med Clin North Am. 2018;102(1):183–197.
   PubMed Web of Science ®Google Scholar
• Anderson JW, Konz EC, Frederich RC, et al. Long-term weight-loss maintenance: a meta-analysis of US studies. Am J Clin Nutr. 2001;74(5):579–584.
   PubMed Web of Science ®Google Scholar
• Godziuk K, Prado CM, Beaupre L, et al. A critical review of weight loss recommendations before total knee arthroplasty. Joint Bone Spine. 2021;88(2):105114.
   PubMed Web of Science ®Google Scholar
• Yanovski SZ, Yanovski JA. Progress in pharmacotherapy for obesity. JAMA. 2021;326(2):129–130.
   PubMed Web of Science ®Google Scholar
• Müller TD, Blüher M, Tschöp MH, et al. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022;21(3):201–223.
   PubMed Web of Science ®Google Scholar
• Son JW, Kim S. Comprehensive review of current and upcoming anti-obesity drugs. Diabetes Metab J. 2020;44(6):802–818.
   PubMed Web of Science ®Google Scholar
• Messier SP, Pater M, Beavers DP, et al. Influences of alignment and obesity on knee joint loading in osteoarthritic gait. Osteoarthritis Cartilage. 2014;22(7):912–917.
   PubMed Web of Science ®Google Scholar
• Messier SP, Gutekunst DJ, Davis C, et al. Weight loss reduces knee-joint loads in overweight and obese older adults with knee osteoarthritis. Arthritis Rheum. 2005;52(7):2026–2032.
   PubMed Web of Science ®Google Scholar
• Aaboe J, Bliddal H, Messier SP, et al. Effects of an intensive weight loss program on knee joint loading in obese adults with knee osteoarthritis. Osteoarthritis Cartilage. 2011;19(7):822–828.
   PubMed Web of Science ®Google Scholar
• Munugoda IP, Beavers DP, Wirth W, et al. The effect of weight loss on the progression of meniscal extrusion and size in knee osteoarthritis: a post-hoc analysis of the Intensive Diet and Exercise for Arthritis (IDEA) trial. Osteoarthritis Cartilage. 2020;28(4):410–417.
   PubMed Web of Science ®Google Scholar
• Vincent HK, Heywood K, Connelly J, et al. Obesity and weight loss in the treatment and prevention of osteoarthritis. Pm R. 2012;4:S59–67.
   PubMedGoogle Scholar
• Miyatake N, Fujii M, Nishikawa H, et al. Clinical evaluation of muscle strength in 20-79-years-old obese Japanese. Diabetes Res Clin Pract. 2000;48(1):15–21.
   PubMed Web of Science ®Google Scholar
• Bennell KL, Hunt MA, Wrigley TV, et al. Role of muscle in the genesis and management of knee osteoarthritis. Rheum Dis Clin North Am. 2008;34(3):731–754.
   PubMed Web of Science ®Google Scholar
• Messier SP, Beavers DP, Mihalko SL, et al. The effects of intensive dietary weight loss and exercise on gait in overweight and obese adults with knee osteoarthritis. The Intensive Diet and Exercise for Arthritis (IDEA) trial. J Biomech. 2020;98:109477.
   PubMed Web of Science ®Google Scholar
• Zhang K, Wang L, Liu Z, et al. Mechanosensory and mechanotransductive processes mediated by ion channels in articular chondrocytes: potential therapeutic targets for osteoarthritis. Channels (Austin). 2021;15(1):339–359.
   PubMed Web of Science ®Google Scholar
• Ramage L, Nuki G, Salter DM. Signalling cascades in mechanotransduction: cell-matrix interactions and mechanical loading. Scand J Med Sci Sports. 2009;19(4):457–469.
   PubMed Web of Science ®Google Scholar
• Chen L, Yao F, Wang T, et al. Horizontal fissuring at the osteochondral interface: a novel and unique pathological feature in patients with obesity-related osteoarthritis. Ann Rheum Dis. 2020;79:811–818.
   PubMed Web of Science ®Google Scholar
• Ouchi N, Parker JL, Lugus JJ, et al. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11(2):85–97.
   PubMed Web of Science ®Google Scholar
• Sowers MR, Karvonen-Gutierrez CA. The evolving role of obesity in knee osteoarthritis. Curr Opin Rheumatol. 2010;22(5):533–537.
   PubMed Web of Science ®Google Scholar
• Pearson MJ, Herndler-Brandstetter D, Tariq MA, et al. IL-6 secretion in osteoarthritis patients is mediated by chondrocyte-synovial fibroblast cross-talk and is enhanced by obesity. Sci Rep. 2017;7(1):3451.
   PubMedGoogle Scholar
• Nanus DE, Wijesinghe SN, Pearson MJ, et al. Regulation of the inflammatory synovial fibroblast phenotype by metastasis-associated lung adenocarcinoma transcript 1 long noncoding RNA in obese patients with osteoarthritis. Arthritis Rheumatol. 2020;72:609–619.
   PubMed Web of Science ®Google Scholar
• Philp AM, Collier RL, Grover LM, et al. Resistin promotes the abnormal Type I collagen phenotype of subchondral bone in obese patients with end stage Hip osteoarthritis. Sci Rep. 2017;7(1):4042.
   PubMedGoogle Scholar
• Wang X, Hunter D, Xu J, et al. Metabolic triggered inflammation in osteoarthritis. Osteoarthritis Cartilage. 2015;23(1):22–30.
   PubMed Web of Science ®Google Scholar
• Loukov D, Karampatos S, Maly MR, et al. Monocyte activation is elevated in women with knee-osteoarthritis and associated with inflammation, BMI and pain. Osteoarthritis Cartilage. 2018;26(2):255–263.
   PubMed Web of Science ®Google Scholar
• Sun AR, Udduttula A, Li J, et al. Cartilage tissue engineering for obesity-induced osteoarthritis: physiology, challenges, and future prospects. J Orthop Translat. 2020;26:3–15.
   PubMed Web of Science ®Google Scholar
• Landsmeer MLA, de Vos BC, van der Plas P, et al. Effect of weight change on progression of knee OA structural features assessed by MRI in overweight and obese women. Osteoarthritis Cartilage. 2018;26(12):1666–1674.
   PubMed Web of Science ®Google Scholar
• Sun AR, Panchal SK, Friis T, et al. Obesity-associated metabolic syndrome spontaneously induces infiltration of pro-inflammatory macrophage in synovium and promotes osteoarthritis. PLoS One. 2017;12(8):e0183693.
   PubMed Web of Science ®Google Scholar
• Mitchell NS, Catenacci VA, Wyatt HR, et al. Obesity: overview of an epidemic. Psychiatr Clin North Am. 2011;34(4):717–732.
   PubMed Web of Science ®Google Scholar
• Finch CF, Kemp JL, Clapperton AJ. The incidence and burden of hospital-treated sports-related injury in people aged 15+ years in Victoria, Australia, 2004-2010: a future epidemic of osteoarthritis? Osteoarthritis Cartilage. 2015;23(7):1138–1143.
   PubMed Web of Science ®Google Scholar
• Lewis-Faning E, Fletcher E. A statistical study of 1,000 cases of chronic rheumatism-part III. Postgrad Med J. 1945;21(234):137–146.
   PubMedGoogle Scholar
• Reyes C, Leyland KM, Peat G, et al. Association between overweight and obesity and risk of clinically diagnosed knee, hip, and hand osteoarthritis: a population-based cohort study. Arthritis Rheumatol. 2016;68(8):1869–1875.
   PubMed Web of Science ®Google Scholar
• Jiang L, Tian W, Wang Y, et al. Body mass index and susceptibility to knee osteoarthritis: a systematic review and meta-analysis. Joint Bone Spine. 2012;79:291–297.
   PubMed Web of Science ®Google Scholar
• Silverwood V, Blagojevic-Bucknall M, Jinks C, et al. Current evidence on risk factors for knee osteoarthritis in older adults: a systematic review and meta-analysis. Osteoarthritis Cartilage. 2015;23(4):507–515.
   PubMed Web of Science ®Google Scholar
• Felson DT, Zhang Y, Anthony JM, et al. Weight loss reduces the risk for symptomatic knee osteoarthritis in women. The Framingham study. Ann Intern Med. 1992;116(7):535–539.
   PubMed Web of Science ®Google Scholar
• Chu IJH, Lim AYT, Clw N. Effects of meaningful weight loss beyond symptomatic relief in adults with knee osteoarthritis and obesity: a systematic review and meta-analysis. Obes Rev. 2018;19:1597–1607.
   PubMed Web of Science ®Google Scholar
• Riddle DL, Stratford PW. Body weight changes and corresponding changes in pain and function in persons with symptomatic knee osteoarthritis: a cohort study. Arthritis Care Res (Hoboken). 2013;65(1):15–22.
   PubMed Web of Science ®Google Scholar
• Messier SP, Resnik AE, Beavers DP, et al. Intentional weight loss in overweight and obese patients with knee osteoarthritis: is more better? Arthritis Care Res (Hoboken). 2018;70(11):1569–1575.
   PubMed Web of Science ®Google Scholar
• Hunter DJ, Beavers DP, Eckstein F, et al. The intensive diet and exercise for arthritis (IDEA) trial: 18-month radiographic and MRI outcomes. Osteoarthritis Cartilage. 2015;23(7):1090–1098.
   PubMed Web of Science ®Google Scholar
• Wenger A, Englund M, Wirth W, et al. Relationship of 3D meniscal morphology and position with knee pain in subjects with knee osteoarthritis: a pilot study. Eur Radiol. 2012;22:211–220.
   PubMed Web of Science ®Google Scholar
• Richette P, Poitou C, Garnero P, et al. Benefits of massive weight loss on symptoms, systemic inflammation and cartilage turnover in obese patients with knee osteoarthritis. Ann Rheum Dis. 2011;70(1):139–144.
   PubMed Web of Science ®Google Scholar
• Anandacoomarasamy A, Leibman S, Smith G, et al. Weight loss in obese people has structure-modifying effects on medial but not on lateral knee articular cartilage. Ann Rheum Dis. 2012;71(1):26–32.
   PubMed Web of Science ®Google Scholar
• Teichtahl AJ, Wluka AE, Tanamas SK, et al. Weight change and change in tibial cartilage volume and symptoms in obese adults. Ann Rheum Dis. 2015;74(6):1024–1029.
   PubMed Web of Science ®Google Scholar
• Gersing AS, Schwaiger BJ, Nevitt MC, et al. Is weight loss associated with less progression of changes in knee articular cartilage among obese and overweight patients as assessed with MR imaging over 48 months? Data from the osteoarthritis initiative. Radiology. 2017;284(2):508–520.
   PubMed Web of Science ®Google Scholar
• Gersing AS, Schwaiger BJ, Nevitt MC, et al. Weight loss regimen in obese and overweight individuals is associated with reduced cartilage degeneration: 96-month data from the osteoarthritis initiative. Osteoarthritis Cartilage. 2019;27(6):863–870.
   PubMed Web of Science ®Google Scholar
• Daugaard CL, Hangaard S, Bartels EM, et al. The effects of weight loss on imaging outcomes in osteoarthritis of the Hip or knee in people who are overweight or obese: a systematic review. Osteoarthritis Cartilage. 2020;28(1):10–21.
   PubMed Web of Science ®Google Scholar
• Administration FaD. Guidance for the clinical evaluation of weight-control drugs. 1996.
   Google Scholar
• Administration FaD. Draft guidance for industry on developing products for weight management. Edited by; 2007.
   Google Scholar
• Colman E. Food and drug administration’s obesity drug guidance document. Circulation. 2012;125(17):2156–2164.
   PubMed Web of Science ®Google Scholar
• Colman E. Anorectics on trial: a half century of federal regulation of prescription appetite suppressants. Ann Intern Med. 2005;143(5):380–385.
   PubMed Web of Science ®Google Scholar
• Hauptman J, Lucas C, Boldrin MN, et al. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med. 2000;9(2):160–167.
   PubMedGoogle Scholar
• Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595–605.
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11–22.
   PubMed Web of Science ®Google Scholar
• Administration FaD. FDA approves first treatment for weight management for people with certain rare genetic conditions. 2020.
   Google Scholar
• Administration FaD. FDA approves new drug treatment for chronic weight management, First Since 2014. 2021.
   Google Scholar
• Tak YJ, Lee SY. Long-term efficacy and safety of anti-obesity treatment: where do we stand? Curr Obes Rep. 2021;10(1):14–30.
   PubMed Web of Science ®Google Scholar
• James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363(10):905–917.
   PubMed Web of Science ®Google Scholar
• Sharretts J, Galescu O, Gomatam S, et al. Cancer risk associated with lorcaserin — the FDA’s review of the CAMELLIA-TIMI 61 trial. N Engl J Med. 2020;383(11):1000–1002.
   PubMed Web of Science ®Google Scholar
• Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American college of cardiology/American Heart Association task force on practice guidelines and the obesity society. Circulation. 2014;129(25_suppl_2):S102–138.
   PubMed Web of Science ®Google Scholar
• Garvey WT, Mechanick JI, Brett EM, et al. American Association of clinical endocrinologists and American college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22 Suppl 3(Suppl 3):1–203.
   PubMedGoogle Scholar
• Zhi J, Melia AT, Guerciolini R, et al. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther. 1994;56(1):82–85.
   PubMed Web of Science ®Google Scholar
• Carrière F, Renou C, Ransac S, et al. Inhibition of gastrointestinal lipolysis by Orlistat during digestion of test meals in healthy volunteers. Am J Physiol Gastrointest Liver Physiol. 2001;281(1):G16–28.
   PubMed Web of Science ®Google Scholar
• Williams G. Orlistat over the counter. BMJ. 2007;335(7631):1163–1164.
   PubMedGoogle Scholar
• Rössner S, Sjöström L, Noack R, et al., European Orlistat Obesity Study Group. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. Obes Res. 2000;8(1):49–61.
   PubMedGoogle Scholar
• Rucker D, Padwal R, Li SK, et al. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ. 2007;335:1194–1199.
   PubMed Web of Science ®Google Scholar
• Sahebkar A, Simental-Mendía LE, Reiner Ž, et al. Effect of orlistat on plasma lipids and body weight: a systematic review and meta-analysis of 33 randomized controlled trials. Pharmacol Res. 2017;122:53–65.
   PubMed Web of Science ®Google Scholar
• Sahebkar A, Simental-Mendía LE, Kovanen PT, et al. Effects of orlistat on blood pressure: a systematic review and meta-analysis of 27 randomized controlled clinical trials. J Am Soc Hypertens. 2018;12(2):80–96.
   PubMed Web of Science ®Google Scholar
• Morris M, Lane P, Lee K, et al. An integrated analysis of liver safety data from orlistat clinical trials. Obes Facts. 2012;5(4):485–494.
   PubMed Web of Science ®Google Scholar
• Singh AK, Singh R. Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized controlled trials of anti-obesity drugs. Expert Rev Clin Pharmacol. 2020;13(1):53–64.
   PubMed Web of Science ®Google Scholar
• Tchang BG, Tarazi MS, Aras M, et al. An update on pharmacotherapeutic strategies for obesity. Expert Opin Pharmacother. 2021;22(10):1305–1318.
   PubMed Web of Science ®Google Scholar
• Bays H. Phentermine, topiramate and their combination for the treatment of adiposopathy (‘sick fat’) and metabolic disease. Expert Rev Cardiovasc Ther. 2010;8:1777–1801.
   PubMedGoogle Scholar
• M-f L, Cheung BM. Rise and fall of anti-obesity drugs. World J Diabetes. 2011;2:19–23.
   PubMedGoogle Scholar
• Nelson DL, Gehlert DR. Central nervous system biogenic amine targets for control of appetite and energy expenditure. Endocrine. 2006;29:49–60.
   PubMed Web of Science ®Google Scholar
• Verrotti A, Scaparrotta A, Agostinelli S, et al. Topiramate-induced weight loss: a review. Epilepsy Res. 2011;95:189–199.
   PubMed Web of Science ®Google Scholar
• Jordan J, Astrup A, Engeli S, et al. Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity. J Hypertens. 2014;32:1178–1188.
   PubMed Web of Science ®Google Scholar
• Klein S, and Romijn JA. Chapter 36 - obesity. In: Melmed S, Polonsky KS, Larsen PR, et al., editors. Williams textbook of endocrinology. 13th ed. Elsevier India; 2016. p. 1633–1659.
   Google Scholar
• Qsymia prescribing information, vivus Inc, Mountain View, California. Edited by; 2014. vol 2021.
   Google Scholar
• Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95:297–308.
   PubMed Web of Science ®Google Scholar
• Khera R, Pandey A, Chandar AK, et al. Effects of weight-loss medications on cardiometabolic risk profiles: a systematic review and network meta-analysis. Gastroenterology. 2018;154:1309–1319.e1307.
   PubMed Web of Science ®Google Scholar
• Khera R, Murad MH, Chandar AK, et al. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. Jama. 2016;315:2424–2434.
   PubMed Web of Science ®Google Scholar
• Siebenhofer A, Winterholer S, Jeitler K, et al. Long-term effects of weight-reducing drugs in people with hypertension. Cochrane Database Syst Rev. 2021;1:Cd007654.
   PubMedGoogle Scholar
• Lei XG, Ruan JQ, Lai C, et al. Efficacy and safety of phentermine/Topiramate in adults with overweight or obesity: a systematic review and meta-analysis. Obesity (Silver Spring). 2021;29(6):985–994.
   PubMed Web of Science ®Google Scholar
• Day C. Chapter 26 - New therapies in obesity. In: Weaver JU, editor. Practical guide to obesity medicine. USA: Elsevier; 2018. p. 271–279.
   Google Scholar
• Woloshin S, Schwartz LM. The new weight-loss drugs, lorcaserin and phentermine-topiramate: slim pickings? JAMA Intern Med. 2014;174(4):615–619.
   PubMed Web of Science ®Google Scholar
• Lewis KH, Fischer H, Ard J, et al. Safety and effectiveness of longer-term phentermine use: clinical outcomes from an electronic health record cohort. Obesity (Silver Spring). 2019;27(4):591–602.
   PubMed Web of Science ®Google Scholar
• Agency EM. Refusal of the marketing authorisation for Qsiva (Phentermine/Topiramate). Outcome of re-examination. 2013.
   Google Scholar
• Greenway FL, Whitehouse MJ, Guttadauria M, et al. Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring). 2009;17(1):30–39.
   PubMed Web of Science ®Google Scholar
• Billes SK, Greenway FL. Combination therapy with naltrexone and bupropion for obesity. Expert Opin Pharmacother. 2011;12(11):1813–1826.
   PubMed Web of Science ®Google Scholar
• Padwal R. Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity. Curr Opin Invest Drugs. 2009;10(10):1117–1125.
   PubMed Web of Science ®Google Scholar
• Chao AM, Wadden TA, Berkowitz RI, et al. The risk of cardiovascular complications with current obesity drugs. Expert Opin Drug Saf. 2020;19(9):1095–1104.
   PubMed Web of Science ®Google Scholar
• Sposito AC, Bonilha I, Luchiari B, et al. Cardiovascular safety of naltrexone and bupropion therapy: systematic review and meta-analyses. Obes Rev. 2021;22(6):e13224.
   PubMed Web of Science ®Google Scholar
• Onakpoya IJ, Lee JJ, Mahtani KR, et al. Naltrexone-bupropion (Mysimba) in management of obesity: a systematic review and meta-analysis of unpublished clinical study reports. Br J Clin Pharmacol. 2020;86(4):646–667.
   PubMed Web of Science ®Google Scholar
• Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740–756.
   PubMed Web of Science ®Google Scholar
• Kanoski SE, Hayes MR, Skibicka KP. GLP-1 and weight loss: unraveling the diverse neural circuitry. Am J Physiol Regul Integr Comp Physiol. 2016;310(10):R885–895.
   PubMed Web of Science ®Google Scholar
• Deacon CF, Nauck MA, Toft-Nielsen M, et al. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes. 1995;44(9):1126–1131.
   PubMed Web of Science ®Google Scholar
• Agersø H, Jensen LB, Elbrønd B, et al. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia. 2002;45(2):195–202.
   PubMed Web of Science ®Google Scholar
• Administration FaD. SAXENDA (liraglutide [rDNA origin] injection), solution for subcutaneous use. 2014.
   Google Scholar
• Davies MJ, Aronne LJ, Caterson ID, et al. Liraglutide and cardiovascular outcomes in adults with overweight or obesity: a post hoc analysis from SCALE randomized controlled trials. Diabetes Obes Metab. 2018;20:734–739.
   PubMed Web of Science ®Google Scholar
• O’Neil PM, Aroda VR, Astrup A, et al. Neuropsychiatric safety with liraglutide 3.0 mg for weight management: results from randomized controlled phase 2 and 3a trials. Diabetes Obes Metab. 2017;19(11):1529–1536.
   PubMed Web of Science ®Google Scholar
• Piccoli GF, Mesquita LA, Stein C, et al. Do GLP-1 receptor agonists increase the risk of breast cancer? A systematic review and meta-analysis. J Clin Endocrinol Metab. 2021;106(3):912–921.
   PubMed Web of Science ®Google Scholar
• Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol (Lausanne). 2019;10:155.
   PubMed Web of Science ®Google Scholar
• Lau J, Bloch P, Schäffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(18):7370–7380.
   PubMed Web of Science ®Google Scholar
• Capehorn MS, Catarig AM, Furberg JK, et al. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2020;46(2):100–109.
   PubMed Web of Science ®Google Scholar
• Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989.
   PubMed Web of Science ®Google Scholar
• Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971–984.
   PubMed Web of Science ®Google Scholar
• Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. Jama. 2021;325(14):1403–1413.
   PubMed Web of Science ®Google Scholar
• Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. Jama. 2021;325(14):1414–1425.
   PubMed Web of Science ®Google Scholar
• Tsapas A, Karagiannis T, Kakotrichi P, et al. Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Obesity Metab. 2021;23(9):2116–2124.
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–1844.
   PubMed Web of Science ®Google Scholar
• Huvenne H, Dubern B, Clément K, et al. Rare genetic forms of obesity: clinical approach and current treatments in 2016. Obes Facts. 2016;9(3):158–173.
   PubMed Web of Science ®Google Scholar
• Stutzmann F, Tan K, Vatin V, et al. Prevalence of melanocortin-4 receptor deficiency in Europeans and their age-dependent penetrance in multigenerational pedigrees. Diabetes. 2008;57(9):2511–2518.
   PubMed Web of Science ®Google Scholar
• Clément K, van den Akker E, Argente J, et al. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol. 2020;8(12):960–970.
   PubMed Web of Science ®Google Scholar
• Pharmaceuticals. R. Rhythm pharmaceuticals announces positive topline results from pivotal phase 3 clinical trial evaluating setmelanotide in Bardet-Biedl and Alström syndromes. 2020.
   Google Scholar
• Markham A. Setmelanotide: first Approval. Drugs. 2021;81(3):397–403.
   PubMed Web of Science ®Google Scholar
• Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, Hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019;27(11):1578–1589.
   PubMed Web of Science ®Google Scholar
• Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2020;72(2):149–162.
   PubMed Web of Science ®Google Scholar
• Ryan DH, Yockey SR. Weight loss and improvement in comorbidity: differences at 5%, 10%, 15%, and over. Curr Obes Rep. 2017;6(2):187–194.
   PubMed Web of Science ®Google Scholar
• Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. Expert panel on the identification, evaluation, and treatment of overweight in adults. Am J Clin Nutr. 1998;68(4):899–917.
   PubMed Web of Science ®Google Scholar
• Christensen R, Bartels EM, Astrup A, et al. Effect of weight reduction in obese patients diagnosed with knee osteoarthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2007;66(4):433–439.
   PubMed Web of Science ®Google Scholar
• Inam SHA, Riaz B, Jamil H, et al. Do patients with osteoarthritis get weight loss counseling? Cureus. 2020;12(11):e11502–e11502.
   PubMed Web of Science ®Google Scholar
• Puhl RM, Heuer CA. The stigma of obesity: a review and update. Obesity (Silver Spring). 2009;17(5):941–964.
   PubMed Web of Science ®Google Scholar
• Kanj A, Levine D. Overcoming obesity: weight-loss drugs are underused. Cleve Clin J Med. 2020;87(10):602–604.
   PubMed Web of Science ®Google Scholar
• Chen J, Xie -J-J, Shi K-S, et al. Glucagon-like peptide-1 receptor regulates endoplasmic reticulum stress-induced apoptosis and the associated inflammatory response in chondrocytes and the progression of osteoarthritis in rat. Cell Death Dis. 2018;9(2):212.
   PubMedGoogle Scholar
• Que Q, Guo X, Zhan L, et al. The GLP-1 agonist, liraglutide, ameliorates inflammation through the activation of the PKA/CREB pathway in a rat model of knee osteoarthritis. J Inflamm (Lond). 2019;16(1):13.
   PubMedGoogle Scholar
• Gudbergsen H, Overgaard A, Henriksen M, et al., Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: a randomized controlled trial. Am J Clin Nutr. 113(2): 314–323. 2021.
   PubMed Web of Science ®Google Scholar
• Ganguly R, Tian Y, Kong SX, et al. Persistence of newer anti-obesity medications in a real-world setting. Diabetes Res Clin Pract. 2018;143:348–356.
   PubMed Web of Science ®Google Scholar
• Association AD. 8. Obesity management for the treatment of Type 2 diabetes: standards of medical care in diabetes—2020. Diabetes Care. 2019;43:S89–S97.
   Web of Science ®Google Scholar
• Canuto R, Garcez A, de Souza Rv, et al. Nutritional intervention strategies for the management of overweight and obesity in primary health care: a systematic review with meta-analysis. Obes Rev. 2021;22(3):e13143.
   PubMed Web of Science ®Google Scholar
• Salari N, Jafari S, Darvishi N, et al. The best drug supplement for obesity treatment: a systematic review and network meta-analysis. Diabetol Metab Syndr. 2021;13(1):110.
   PubMed Web of Science ®Google Scholar
• Patel DK, Stanford FC. Safety and tolerability of new-generation anti-obesity medications: a narrative review. Postgrad Med. 2018;130(2):173–182.
   PubMed Web of Science ®Google Scholar
• Acosta A, Streett S, Kroh MD, et al. White paper AGA: POWER — practice guide on obesity and weight management, education, and resources. Clin Gastroenterol Hepatol. 2017;15(5):631–649.e610.
   PubMed Web of Science ®Google Scholar
• Acosta A, Camilleri M, Abu Dayyeh B, et al. Selection of antiobesity medications based on phenotypes enhances weight loss: a pragmatic trial in an obesity clinic. Obesity (Silver Spring). 2021;29(4):662–671.
   PubMed Web of Science ®Google Scholar
• Tak YJ, Lee SY. Anti-obesity drugs: long-term efficacy and safety: an updated review. World J Mens Health. 2021;39(2):208–221.
   PubMedGoogle Scholar
• Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study. Int J Obes (Lond). 2013;37(11):1443–1451.
   PubMed Web of Science ®Google Scholar
• Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155–161.
   PubMed Web of Science ®Google Scholar
• Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2011;95(2):297–308.
   PubMed Web of Science ®Google Scholar
• le Roux Cw, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389(10077):1399–1409.
   PubMed Web of Science ®Google Scholar
• Field AE, Camargo CA Jr. Ogino S: the merits of subtyping obesity: one size does not fit all. Jama. 2013;310(20):2147–2148.
   PubMed Web of Science ®Google Scholar
• DerSarkissian M, Bhak RH, Huang J, et al. Maintenance of weight loss or stability in subjects with obesity: a retrospective longitudinal analysis of a real-world population. Curr Med Res Opin. 2017;33(6):1105–1110.
   PubMed Web of Science ®Google Scholar
• Hartmann-Boyce J, Theodoulou A, Oke JL, et al. Association between characteristics of behavioural weight loss programmes and weight change after programme end: systematic review and meta-analysis. Bmj. 2021;374:n1840.
   PubMedGoogle Scholar
• Ahmad NN, Robinson S, Kennedy-Martin T, et al. Clinical outcomes associated with anti-obesity medications in real-world practice: a systematic literature review. Obesity Rev. 2021;22(11):e13326.
   PubMed Web of Science ®Google Scholar
• Hainer V, Aldhoon-Hainerová I. Tolerability and safety of the new anti-obesity medications. Drug Saf. 2014;37(9):693–702.
   PubMed Web of Science ®Google Scholar
• Elangovan A, Shah R, Smith ZL. Pharmacotherapy for obesity-trends using a population level national database. Obes Surg. 2021;31(3):1105–1112.
   PubMed Web of Science ®Google Scholar
• Jiang L, Xie X, Wang Y, et al. Body mass index and hand osteoarthritis susceptibility: an updated meta-analysis. Int J Rheum Dis. 2016;19(12):1244–1254.
   PubMed Web of Science ®Google Scholar
• Jiang L, Rong J, Wang Y, et al. The relationship between body mass index and Hip osteoarthritis: a systematic review and meta-analysis. Joint Bone Spine. 2011;78(2):150–155.
   PubMed Web of Science ®Google Scholar
• Magnusson K, Slatkowsky-Christensen B, van der Heijde D, et al. Body mass index and progressive hand osteoarthritis: data from the Oslo hand osteoarthritis cohort. Scand J Rheumatol. 2015;44(4):331–336.
   PubMed Web of Science ®Google Scholar
• Visser AW, de Mutsert R, le Cessie S, et al. The relative contribution of mechanical stress and systemic processes in different types of osteoarthritis: the NEO study. Ann Rheum Dis. 2015;74(10):1842–1847.
   PubMed Web of Science ®Google Scholar
• Silvestre MP, Rodrigues AM, Canhão H, et al. Cross-talk between diet-associated dysbiosis and hand osteoarthritis. Nutrients. 2020;12(11):3469.
   PubMed Web of Science ®Google Scholar
• Robson EK, Hodder RK, Kamper SJ, et al. Effectiveness of weight-loss interventions for reducing pain and disability in people with common musculoskeletal disorders: a systematic review with meta-analysis. J Orthop Sports Phys Ther. 2020;50(6):319–333.
   PubMed Web of Science ®Google Scholar
• Polidori D, Sanghvi A, Seeley RJ, et al. How strongly does appetite counter weight loss? Quantification of the feedback control of human energy intake. Obesity. 2016;24(11):2289–2295.
   PubMed Web of Science ®Google Scholar
• Löffler MC, Betz MJ, Blondin DP, et al. Challenges in tackling energy expenditure as obesity therapy: from preclinical models to clinical application. Mol Metab. 2021;51:101237.
   PubMed Web of Science ®Google Scholar
• Donnelly JE, Blair SN, Jakicic JM, et al. Appropriate physical activity intervention strategies for weight loss and prevention of weight regain for adults. Med Sci Sports Exercise. 2009;41(2):459–471.
   PubMed Web of Science ®Google Scholar
• Pontzer H, Durazo-Arvizu R, Dugas Lara R, et al. Constrained total energy expenditure and metabolic adaptation to physical activity in adult humans. Curr Biol. 2016;26(3):410–417.
   PubMed Web of Science ®Google Scholar
• Foster-Schubert KE, Alfano CM, Duggan CR, et al. Effect of diet and exercise, alone or combined, on weight and body composition in overweight-to-obese postmenopausal women. Obesity. 2012;20(8):1628–1638.
   PubMed Web of Science ®Google Scholar
• Hall M, Castelein B, Wittoek R, et al. Diet-induced weight loss alone or combined with exercise in overweight or obese people with knee osteoarthritis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2019;48(5):765–777.
   PubMed Web of Science ®Google Scholar
• Singh N, Stewart RAH, Benatar JR. Intensity and duration of lifestyle interventions for long-term weight loss and association with mortality: a meta-analysis of randomised trials. BMJ open. 2019;9(8):e029966–e029966.
   PubMed Web of Science ®Google Scholar
• Look ARG. Eight-year weight losses with an intensive lifestyle intervention: the look AHEAD study. Obesity (Silver Spring). 2014;22:5–13.
   PubMed Web of Science ®Google Scholar
• Kuczmarski RJ, Flegal KM. Criteria for definition of overweight in transition: background and recommendations for the United States. Am J Clin Nutr. 2000;72(5):1074–1081.
   PubMed Web of Science ®Google Scholar
• Wolfe BM, Kvach E, Eckel RH. Treatment of obesity: weight loss and bariatric surgery. Circ Res. 2016;118(11):1844–1855.
   PubMed Web of Science ®Google Scholar
• Yermilov I, McGory ML, Shekelle PW, et al. Appropriateness criteria for bariatric surgery: beyond the NIH guidelines. Obesity (Silver Spring). 2009;17(8):1521–1527.
   PubMed Web of Science ®Google Scholar
• Lawley J. Weighing up the evidence: a meta-analysis and therapeutic audit of the treatments for obesity. Biosci Horiz. 2014: 7
   Google Scholar
• O’Brien PE, Hindle A, Brennan L, et al. Long-term outcomes after bariatric surgery: a systematic review and meta-analysis of weight loss at 10 or more years for all bariatric procedures and a single-centre review of 20-year outcomes after adjustable gastric banding. Obes Surg. 2019;29(1):3–14.
   PubMed Web of Science ®Google Scholar
• Franz MJ, VanWormer JJ, Crain AL, et al. Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. J Am Diet Assoc. 2007;107(10):1755–1767.
   PubMed Web of Science ®Google Scholar
• Vosoughi K, Atieh J, and Khanna L, et al. Association of glucagon-like peptide 1 analogs and agonists administered for obesity with weight loss and adverse events: a systematic review and network meta-analysis. EClinicalMedicine. 2021;42:101213.
   PubMedGoogle Scholar
• Gloy VL, Briel M, Bhatt DL, et al. Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. BMJ. 2013;347(oct22 1):f5934.
   PubMedGoogle Scholar
• Courcoulas AP, Christian NJ, Belle SH, et al. Weight change and health outcomes at 3 years after bariatric surgery among individuals with severe obesity. Jama. 2013;310(22):2416–2425.
   PubMed Web of Science ®Google Scholar
• Arterburn DE, Telem DA, Kushner RF. Courcoulas AP: benefits and risks of bariatric surgery in adults: a review. Jama. 2020;324(9):879–887.
   PubMed Web of Science ®Google Scholar
• Jakobsen GS, Småstuen MC, Sandbu R, et al. Association of bariatric surgery vs medical obesity treatment with long-term medical complications and obesity-related comorbidities. Jama. 2018;319(3):291–301.
   PubMed Web of Science ®Google Scholar
• Ha J, Kwon Y, Kwon JW, et al. Micronutrient status in bariatric surgery patients receiving postoperative supplementation per guidelines: insights from a systematic review and meta-analysis of longitudinal studies. Obes Rev. 2021;22(7):e13249.
   PubMed Web of Science ®Google Scholar
• Avenell A, Robertson C, Skea Z, et al. Bariatric surgery, lifestyle interventions and orlistat for severe obesity: the REBALANCE mixed-methods systematic review and economic evaluation. Health Technol Assess. 2018;22(68):1–246.
   PubMed Web of Science ®Google Scholar
• Noparatayaporn P, Thavorncharoensap M, Chaikledkaew U, et al. Incremental net monetary benefit of bariatric surgery: systematic review and meta-analysis of cost-effectiveness evidences. Obes Surg. 2021;31(7):3279–3290.
   PubMed Web of Science ®Google Scholar
• Afshin A, Forouzanfar MH, Reitsma MB, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377:13–27.
   PubMed Web of Science ®Google Scholar
• Franz MJ, Boucher JL, Rutten-Ramos S, et al. Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials. J Acad Nutr Diet. 2015;115(9):1447–1463.
   PubMed Web of Science ®Google Scholar
• Hamman RF, Wing RR, Edelstein SL, et al. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care. 2006;29(9):2102–2107.
   PubMed Web of Science ®Google Scholar
• Gummesson A, Nyman E, Knutsson M, et al. Effect of weight reduction on glycated haemoglobin in weight loss trials in patients with type 2 diabetes. Diabetes Obes Metab. 2017;19(9):1295–1305.
   PubMed Web of Science ®Google Scholar
• Haase CL, Lopes S, Olsen AH, et al. Weight loss and risk reduction of obesity-related outcomes in 0.5 million people: evidence from a UK primary care database. Int J Obesity. 2021;45(6):1249–1258.
   Web of Science ®Google Scholar
• Zomer E, Gurusamy K, Leach R, et al. Interventions that cause weight loss and the impact on cardiovascular risk factors: a systematic review and meta-analysis. Obesity Rev. 2016;17(10):1001–1011.
   PubMed Web of Science ®Google Scholar
• Bell K, Parasuraman S, Shah M, et al. Economic implications of weight change in patients with type 2 diabetes mellitus. Am J Manag Care. 2014;20(8):e320–329.
   PubMed Web of Science ®Google Scholar
• Fridman M, Lucas ME, Paprocki Y, et al. Impact of weight change in adults with Type 2 diabetes mellitus: a literature review and critical analysis. Clinicoecon Outcomes Res. 2020;12:555–566.
   PubMed Web of Science ®Google Scholar
• Amundsen MO, Engdahl B, Berg C, et al. Cardiovascular co-medication among users of antiobesity drugs: a population-based study. Pharm World Sci. 2010;32(6):752–758.
   PubMed Web of Science ®Google Scholar
• Counterweight Project T. The impact of obesity on drug prescribing in primary care. Br J Gen Pract. 2005;55:743–749.
   PubMed Web of Science ®Google Scholar
• Lau DC, Teoh H. Impact of current and emerging glucose-lowering drugs on body weight in Type 2 diabetes. Can J Diabetes. 2015;39(Suppl 5):S148–154.
   PubMedGoogle Scholar
• Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13(1):57–65.
   PubMed Web of Science ®Google Scholar
• Kim B-Y, Kang SM, Kang J-H, et al. Current long-term pharmacotherapies for the management of obesity. J Obes Metab Syndr. 2020;29(2):99–109.
   PubMed Web of Science ®Google Scholar